Study Confirms Risk-Adapted CRS Prophylaxis for Acute Leukemia

(MedPage Today) -- Risk-adapted prophylactic tocilizumab (Actemra) proved feasible for reducing the incidence of severe cytokine release syndrome (CRS) in pediatric acute leukemia treated with CAR T-cell therapy, without making the latter less...